Michelle W. Brown-Wong

Lot 1 Kookaburra Circuit, New Lambton Heights
Newcastle, NSW 2305, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Emerging biomarkers for the early detection of high-grade serous tubo-ovarian cancer.

Emerging biomarkers for the early detection of high-grade serous tubo-ovarian cancer.

Journal: Critical reviews in oncology/hematology

Published: October 14, 2025

Repurposing of ivacaftor shows potential to treat ROR1 expressing high-grade serous ovarian cancer.

Repurposing of ivacaftor shows potential to treat ROR1 expressing high-grade serous ovarian cancer.

Journal: Therapeutic advances in medical oncology

Published: May 25, 2025

Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancer.

Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancer.

Journal: Molecular therapy. Oncology

Published: August 28, 2024

Fusobacterium nucleatum: An Overview of Evidence, Demi-Decadal Trends, and Its Role in Adverse Pregnancy Outcomes and Various Gynecological Diseases, including Cancers.

Fusobacterium nucleatum: An Overview of Evidence, Demi-Decadal Trends, and Its Role in Adverse Pregnancy Outcomes and Various Gynecological Diseases, including Cancers.

Journal: Cells

Published: March 07, 2024

ERCC2 mutations alter the genomic distribution pattern of somatic mutations and are independently prognostic in bladder cancer.

ERCC2 mutations alter the genomic distribution pattern of somatic mutations and are independently prognostic in bladder cancer.

Journal: Cell genomics

Published: February 12, 2024

Correction: When is a mutation not a mutation: the case of the c.594-2A>C splice variant in a woman harbouring another BRCA1 mutation in trans.

Correction: When is a mutation not a mutation: the case of the c.594-2A>C splice variant in a woman harbouring another BRCA1 mutation in trans.

Journal: Hereditary cancer in clinical practice

Published: May 31, 2022

Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer.

Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer.

Journal: Cancers

Published: November 04, 2021

Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy.

Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy.

Journal: BMC cancer

Published: August 03, 2021

Investigation of monogenic causes of familial breast cancer: data from the BEACCON case-control study.

Investigation of monogenic causes of familial breast cancer: data from the BEACCON case-control study.

Journal: NPJ breast cancer

Published: October 31, 2020

Targeting DNA Repair in Ovarian Cancer Treatment Resistance.

Targeting DNA Repair in Ovarian Cancer Treatment Resistance.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: January 10, 2020

Global DNA methylation and cognitive and behavioral outcomes at 4 years of age: A cross-sectional study.

Global DNA methylation and cognitive and behavioral outcomes at 4 years of age: A cross-sectional study.

Journal: Brain and behavior

Published: August 12, 2019

BCL-2 family isoforms in apoptosis and cancer.

BCL-2 family isoforms in apoptosis and cancer.

Journal: Cell death & disease

Published: September 23, 2018

Showing 1-12 of 25

Last Updated: 09/26/2026